secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001493152-23-033196
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports FY2023 net loss of $11.7M; cash $11.2M; FDA supports Phase 3
----------------------------------------------------------------------------

- Net loss for FY2023 was $11.7M ($0.47 per share) vs $6.8M ($0.29) in FY2022.
- Cash and cash equivalents at June 30, 2023 were $11.2 million.
- Positive FDA Type B meeting supports advancing ANEB-001 to registrational studies; Phase 3 targeting H1 2024.
- Dosing completed in Part C open-label extension of Phase 2 study; data readout expected Q4 2023.
- Operating expenses in FY2023 were $11.8M, up from $6.8M, driven by R&D and G&A increases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/0001493152-23-033196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer